Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Head & Neck 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 80Paclitaxel 53Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × bintrafusp alfa protein, human × Breast × Clear all
NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 10 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡